Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
== Further reading == Robert Kempa, Plebiscyt 1920 r. w północno-wschodniej części Mazur (na przykładzie powiatu giżyckiego). In Masovia. Pismo poświęcone dziejom Mazur, 4/2001, Giżycko 2001, pp. 149–157 (in Polish) Andreas Kossert, Ostpreussen: Geschichte und Mythos, ISBN 3-88680-808-4 (in German) Andreas Kossert, Religion versus Ethnicity: A Case Study of Nationalism or How Masuria Became a "Borderland", in: Madeleine Hurd (ed.): Borderland Identities: Territory and Belonging in Central, North and East Europe. Eslöv 2006, S. 313–330 Adam Szymanowicz, Udział Oddziału II Sztabu Generalnego Ministerstwa Spraw Wojskowych w pracach plebiscytowych na Warmii, Mazurach i Powiślu w 1920 roku. In Komunikaty Mazursko – Warmińskie, 4/2004, pp. 515–530.(in Polish) Wojciech Wrzesiñsk, Das Recht zur Selbstbestimmung oder der Kampf um staatliche Souveränität – Plebiszit in Ostpreußen 1920 in AHF Informationen Nr. 54 vom 20.09.2000 [2] (in German)
reciprocal translocation A type of chromosomal translocation by which there is a reciprocal exchange of chromosome segments between two or more non-homologous chromosomes. When the exchange of material is evenly balanced, reciprocal translocations are usually harmless.
Football is the most popular sport in Romania with over 219,000 registered players as of 2018. The market for professional football in Romania was roughly €740 million in 2018 according to UEFA. The governing body is the Romanian Football Federation, which belongs to UEFA. The Romania national football team played its first match in 1922 and is one of only four national teams to have taken part in the first three FIFA World Cups, the other three being Brazil, France, and Belgium. Overall, it has played in seven World Cups and had its most successful period during the 1990s, when it finished 6th at the 1994 FIFA World Cup, eventually being ranked 3rd by FIFA in 1997. The most successful club is Steaua București, who were the first Eastern European team to win the UEFA Champions League in 1986, and were runners-up in 1989. Dinamo București reached the UEFA Champions League semi-final in 1984 and the UEFA Cup Winners' Cup semi-final in 1990. Other important Romanian football clubs are Rapid București, UTA Arad, Universitatea Craiova, Petrolul Ploiești, CFR Cluj, Astra Giurgiu, and Viitorul Constanța (the latter having recently merged with FCV Farul Constanța). Tennis is the second most popular sport. Romania reached the Davis Cup finals three times in 1969, 1971 and 1972. The second most popular team sport is handball. The men's team won the handball world championship in 1961, 1964, 1970, 1974 making them the third most successful nation ever in the tournament.
After the collapse of the Soviet Union, there were 910 higher educational institutions on the territory of Ukraine, and over the years there has been a tendency to reduce their number. Despite the decline of universities, the number of university students increased from 881,000 in 1990/1991 to 2.4 million in 2007/2008. Taras Shevchenko National University of Kyiv, founded in 1834 and located in Kyiv, is one of the most prestigious universities in Ukraine. National University of Kharkiv was founded in 1804 in Kharkiv and since then has become one of the largest universities in Eastern Europe.
Intracellular Hbs. These globins reside inside a cell, much like the vertebrate Hb. Multi-subunit Hbs. These globins form complexes and work outside a cell. Multi-domain, multisubunit Hbs. These globins form complexes, work outside a cell, and have multiple globin domains per peptide chain. Erythrocruorin and chlorocruorin belong to the multisubunit Hbs, specifically of the 12-dodecamer type.
Sources: en.wikipedia.org
== In popular culture == In the movie The Bucket List, billionaire health care magnate Edward Cole (played by Jack Nicholson) brings kopi luwak with him on all of his travels but is unaware of how the drink is produced. Carter Chambers (Morgan Freeman) explains how civets defecate kopi luwak coffee beans, and that the gastric juices of the defecated beans give kopi luwak its unique aroma. The Japanese manga series Beastars features an anthropomorphic civet character named Deshico that produces kopi luwak.
== Homology == The various paralogues in a mammal have differing but overlapping substrate specificities and tissue distributions as summarized by Hagenbuch and Meier. These authors also provide a phylogenetic tree of the mammalian members of the family, showing that they fall into five recognizable subfamilies, four of which exhibit deep branching sub-subfamilies. However, all sequences within a subfamily are >60% identical while those between subfamilies are >40% identical. As also shown by Hagenbuch and Meier, all but one (OatP4a1) of the mammalian homologues cluster together, separately from all other animal (insect and worm) homologues. OAT family homologues have been found in other animals but not outside of the animal kingdom. These transporters have been characterized in mammals, but homologues are present in Drosophila melanogaster, Anopheles gambiae, and Caenorhabditis elegans. The mammalian OAT family proteins exhibit a high degree of tissue specificity.
=== Reports from investigative journalists === In 2003, a German investigative journalist sponsored by the British Union for the Abolition of Vivisection (BUAV) filmed 40 hours of undercover footage at the company's primate-testing facility in Münster. Two films were produced, which were shown on German public television in December 2003. The footage showed animal keepers dancing with half-anaesthetized monkeys, making their heads move to the rhythm of the music. It also showed rough treatment of the monkeys by the staff. The monkeys were seen living isolated in small wire cages with little or no natural light and no environmental enrichment, with high noise levels caused by staff shouting and playing the radio, and undergoing surgery with no post-operative care. In response, the company maintained that clips showing different technicians working in different buildings had been edited together, resulting in a sequence of events that did not take place. The company also said there was group housing and pair housing for some monkeys that was not shown. In the films, the treatment of the monkeys was criticized by Jane Goodall. The environment minister for North Rhine-Westphalia asked the public prosecutor to investigate, and said that if the allegations were borne out, the company would lose its licence to keep primates. The company gained an injunction against the video. From April 2004 to March 2005, an undercover technician, sponsored by People for the Ethical Treatment of Animals (PETA), filmed the treatment of monkeys in the company's lab in Vienna, Virginia.
The prominence of traders from Malacca led Melayu to be associated with Muslim traders, and from there became associated with the wider cultural and linguistic group. Malacca and later Johor claimed they were the centre of Malay culture, a position supported by the British which led to the term Malay becoming more usually linked to the Malay peninsula rather than Sumatra. Before the onset of European colonisation, the Malay Peninsula was known natively as Tanah Melayu ('Malay Land'). Under a racial classification created by German scholar Johann Friedrich Blumenbach, the natives of maritime Southeast Asia were grouped into a single category, the Malay race. Following the expedition of French navigator Jules Dumont d'Urville to Oceania in 1826, he later proposed the terms of Malaysia, Micronesia, and Melanesia to the Société de Géographie in 1831, distinguishing these Pacific cultures and island groups from the existing term Polynesia. Dumont d'Urville described Malaysia as "an area commonly known as the East Indies". In 1850, the English ethnologist George Samuel Windsor Earl, writing in the Journal of the Indian Archipelago and Eastern Asia, proposed naming the islands of Southeast Asia as "Melayunesia" or "Indunesia", favouring the former. The name Malaysia gained some use to label what is now the Malay Archipelago.
Sources: en.wikipedia.org
codon A series of three consecutive nucleotides in a coding region of a nucleic acid sequence. Each of these triplets codes for a particular amino acid or stop signal during protein synthesis. DNA and RNA molecules are each written in a language using four "letters" (four different nucleobases), but the language used to construct proteins includes 20 "letters" (20 different amino acids). Codons provide the key that allows these two languages to be translated into each other. In general, each codon corresponds to a single amino acid (or stop signal). The full set of codons is called the genetic code.
=== In cellular biology === It is also used in cellular biology as an inhibitor of the lipid raft-caveolae endocytosis pathway on mammalian cells, at concentrations around 3 μg/ml. Nystatin is also used as a tool by scientists performing "perforated" patch-clamp electrophysiological recordings of cells. When loaded in the recording pipette, it allows for measurement of electrical currents without washing out the intracellular contents, because it forms pores in the cell membrane that are permeable to only monovalent ions, preferably cations such as sodium, potassium, lithium, and cesium.
Early in the 20th century, Dentistry shifted from treatment based therapy to prevention and as such, dentures that were in line with good health became more favourable. Having a clear occupation for dentures alone became a requirement.
=== Alkylation of carboxylic acids and their salts === Trimethyloxonium tetrafluoroborate can be used for esterification of carboxylic acids under conditions where acid-catalyzed reactions are infeasible:
The atherosclerotic process is not well understood. Atherosclerosis is associated with inflammatory processes in the endothelial cells of the vessel wall associated with retained low-density lipoprotein (LDL) particles. This retention may be a cause, an effect, or both of the underlying inflammatory process. The presence of the plaque induces the muscle cells of the blood vessel to stretch, compensating for the additional bulk. The endothelial lining then thickens, increasing the separation between the plaque and the lumen. The thickening somewhat offsets the narrowing caused by the plaque's growth. Moreover, it causes the wall to stiffen and become less compliant to stretching with each heartbeat.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.